Back to Journals » OncoTargets and Therapy » Volume 6
Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
Authors Cho D
Received 28 March 2013
Accepted for publication 16 April 2013
Published 13 June 2013 Volume 2013:6 Pages 679—684
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Daniel C Cho
Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
Abstract: Tyrosine kinase inhibitors with activity against vascular endothelial growth factor receptor 2 are now standard treatment for the majority of patients with advanced renal cell carcinoma. The clinical development of these agents followed by their broad clinical utilization has allowed the creation of large databases to facilitate the identification of prognostic biomarkers and development of prognostic models. While several clinical prognostic models have been created, work continues on identifying novel biomarkers which might be used in conjunction with or even in place of these clinical models. In this review, we discuss the progress thus far in improving on current prognostic models and speculate on possible developments in the near future.
Keywords: renal cancer, prognostic biomarker, VEGF tyrosine kinase inhibitors
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.